Physician profile

Justine Beard

Pediatrics · Richmond, VA

NPI 1417367020

$309.72

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$18.87

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abiomed $111.42 2019
Ironshore Pharmaceuticals INC. $46.92 2019-2020
Kaleo, INC. $34.97 2019
Genentech USA, INC. $27.39 2019-2020
Pfizer INC. $18.87 2023
Sanofi Pasteur INC. $17.61 2019
Arbor Pharmaceuticals, INC. $15.34 2019
Cranial Technologies, INC $14.11 2019
Shire North American Group INC $12.03 2019
Merck Sharp & Dohme LLC $11.06 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Justine Beard

$309.72

in general payments reported 2019-2025

Years
2019-2023
Top company
Abiomed

https://glasscript.com/doctor/5402110/justine-beard

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.